Trial Profile
A Randomized, Double-blind, Placebo-controlled, First-in-Human Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Feb 2021
Price :
$35
*
At a glance
- Drugs Ad26-ZIKV-001 (Primary)
- Indications Zika virus infection
- Focus Adverse reactions; First in man
- Sponsors Janssen Vaccines and Prevention B.V
- 16 Feb 2021 Results published in the Annals of Internal Medicine
- 14 Oct 2019 Status changed from active, no longer recruiting to completed.
- 01 Apr 2019 Planned primary completion date changed from 15 Mar 2019 to 3 Oct 2019.